These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 812544)
1. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine. Jones RJ; Roe EA Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544 [TBL] [Abstract][Full Text] [Related]
2. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers]. Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666 [TBL] [Abstract][Full Text] [Related]
4. Protective activity of immune sera against extracellular slime from Pseudomonas aeruginosa on experimental infection in mice. Sokalska M; Maresz-Babczyszyn J Arch Immunol Ther Exp (Warsz); 1981; 29(5):643-52. PubMed ID: 6812542 [TBL] [Abstract][Full Text] [Related]
5. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes. Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231 [TBL] [Abstract][Full Text] [Related]
6. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein. Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845 [TBL] [Abstract][Full Text] [Related]
7. Protection against Pseudomonas aeruginosa infection by immunisation with fractions of culture filtrates of Ps. aeruginosa. Jones RJ Br J Exp Pathol; 1968 Oct; 49(5):411-20. PubMed ID: 4973304 [No Abstract] [Full Text] [Related]
8. Antibody responses of burned patients immunized with a polyvalent Pseudomonas vaccine. Jones RJ J Hyg (Lond); 1979 Jun; 82(3):453-62. PubMed ID: 109501 [TBL] [Abstract][Full Text] [Related]
9. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection. Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605 [TBL] [Abstract][Full Text] [Related]
10. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection. Okada K; Kawaharajo K; Kasai T; Homma JY Jpn J Exp Med; 1980 Feb; 50(1):53-61. PubMed ID: 6770131 [TBL] [Abstract][Full Text] [Related]
11. Common protective antigen between Pseudomanas aeruginosa and Vibrio cholerae. Yamamoto A; Homma JY; Ghoda A; Ishihara T; Takeuchi S Jpn J Exp Med; 1979 Dec; 49(6):383-90. PubMed ID: 120454 [TBL] [Abstract][Full Text] [Related]
12. Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine. Barclay GR; Yap PL; McClelland DB; Jones RJ; Roe EA; McCann MC; Micklem LR; James K J Med Microbiol; 1986 Feb; 21(1):87-90. PubMed ID: 3081727 [TBL] [Abstract][Full Text] [Related]
13. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection. Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581 [TBL] [Abstract][Full Text] [Related]
14. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice. Moriyama K; Wiener-Kronish JP; Sawa T Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258 [TBL] [Abstract][Full Text] [Related]
15. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa]. Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310 [No Abstract] [Full Text] [Related]
16. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines. Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018 [TBL] [Abstract][Full Text] [Related]
17. Induction in mice of cell-mediated immunity to Pseudomonas aeruginosa by high molecular weight polysaccharide and vinblastine. Pier GB; Markham RB J Immunol; 1982 May; 128(5):2121-5. PubMed ID: 6174622 [TBL] [Abstract][Full Text] [Related]
18. An acellular vaccine from Pseudomonas aeruginosa: homologous and crossed protection between serogroups according to Habs' classification. Berche P; Véron M; Fermanian J; Daoulas-Lebourdelles F; Guégen A Ann Microbiol (Paris); 1979; 130(2):179-88. PubMed ID: 90473 [TBL] [Abstract][Full Text] [Related]
19. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization. Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420 [TBL] [Abstract][Full Text] [Related]
20. The epidemiology of Pseudomonas aeruginosa and the development of a polyvalent vaccine. Pranter W; Staerk J; Zellner R; Zwisler O Prog Immunobiol Stand; 1971; 5():414-8. PubMed ID: 4633968 [No Abstract] [Full Text] [Related] [Next] [New Search]